

Subscription Order Form 2009

Please enter a Subscription to ANTICANCER RESEARCH for Volume 29 (2009).

Annual subscription rates (2009): Institutional, Euro 1,612.00 - online; 1,634.00 - print; 1,682.00 - print & online.

Personal, Euro 763.00 - online; 785.00 - print; 833.00 - print & online. Prices include rapid delivery and insurance.

Please send me the following previous volumes (1-28) at 50% discount on the above rates:

Payment is enclosed. Please invoice.

(Cheques should be made payable to J.G. Delinassios, Athens, Greece)

Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address:

Tel:

Fax: e-mail:

Signature: Date:

Please send this order to ANTICANCER RESEARCH, Editorial Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: journals@iilar-anticancer.org

Special 2009 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2009 on a basis of priority and availability. Effective from January to December 2009.)

ANTICANCER RESEARCH International Journal of Cancer Research and Treatment ISSN: 0250-7005	
Volume 28, Number 6A, November-December 2008	
Contents	
Experimental Studies	
The Impact of Enzymatic Degradation on the Uptake of Differently Sized Therapeutic Molecules. A. ERIKSSON, I. TUFTO, A.B. BIRNNUM, O.S. BRULAND, C. DE LANGE DAVIES (<i>Tromsø, Oslo, Norway</i>)	
Alpha-fetoprotein Expression in Epithelial Ovarian Carcinoma and Non-metaplastic Ovarian Tissue. S. MARKERT, S. LASSMANN, B. GABRIEL, M. KLAAS, M. WERNER, G. GITSCHE, F. KRATZ, A. HASENBURG (<i>Freiburg, Germany</i>)	
Identification of Parental Chromosomes Involved in Translocations BCR-ABL (9;22) and PML-RARA, t(15;17). A. KARANAMOV, P. PULEJAJ, J.R. MCCOLL, J.-U. WALTHER (<i>Münster, Germany; Phoenix, AZ, USA</i>)	
Role of Caspase-3 and Selenite-induced Growth Inhibition of Colorectal Cancer Cells. A.A. THANTY, Y. WU, J. LEE, D.K. MEHTA, A. GARCIA, H.P. KOPPELER, J.V. VADGAMA (<i>Los Angeles, CA, USA</i>)	
Pigmentation, a Marker for Prognosis in Melanoma Patients. L. LIOU, M. TAKANO, T. KUBOTA, H. NISHIMURA, H. HASEGAWA, Y. ISHII, S. NITOU, H. OCHIAI, K. OKABAYASHI, Y. KITAGAWA, M. WATANABE, M. KITAIMA (<i>Tokyo, Japan</i>)	
Radioprotection of Murine Gastrointestinal Epithelium by Interleukin-1α Involves Down-regulation of the Apoptotic Pathway. J. VAN DER BORGH, R. VAN DER CARREYEAU, M.J. EVANS, J.M. KILBURN, N.T.G. BAKKEN, G.N. NANGAMI (<i>Greenville, NC, USA</i>)	
Genomic Profile of Colon Cancer Metastases. G. ZEITOUNI, N. MOURRA, H. BLANCHÉ-KOCH, G. THOMAS, S. OLSCHWANG (<i>Monte-les-Joli; Paris; Marseille, France; Gaithersburg, MD, USA</i>)	
Contents continued on the back cover	

Your link to the essential information on cancer research published in the last 28 years.

- 1981-2008
- 28 volumes
- over 81,000 pages
- over 12,500 original articles
- 571 reviews
- over 53,000 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes

Please complete and send this order form to:

ANTICANCER RESEARCH Editorial Office, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.

Special Subscription Order Form 2009

I am one of the authors of the article published in Anticancer Research Vol....., pp., year

Please enter my personal subscription to Anticancer Research 2009 (Volume 29) at the special Author's rate of Euro 417.00 (print or online); Euro 500.00 (print & online).

Please send me previous Volume No(s) at Euro 208.00 per volume.

Please enter my personal combined 2009 subscription to Anticancer Research (Volume 29), IN VIVO (Volume 23) and CANCER GENOMICS & PROTEOMICS (Volume 6) at Euro 755.00 (print or online); Euro 972.00 (print & online).

My payment is enclosed.

Please send me an invoice.

(Prices include rapid delivery and insurance. Cheques should be made payable to J.G. Delinassios, Athens, Greece).

Name and address:

.....

Tel-Fax:

e-mail:

Date and signature:

CANCER GENOMICS & PROTEOMICS

online from January 2009



www.cgp-journal.com

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 2 (2005) - VOL. 3 (2006)

VOL. 4 (2007) - VOL. 5 (2008) - VOL. 6 (2009)

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 2-4 months from submission or 1-2 months from acceptance.

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, *DLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, SIIC.

Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iiar-anticancer.org (Editorial Office); editor@cgp-journal.com (Managing Editor)

A Selection of Recent Papers

Proteomic Analysis of Archival Breast Cancer Serum. B.A ZEIDAN, R.I. CUTRESS, N. MURRAY, G. COULTON, C. HASTIE, G. PACKHAM, P.A. TOWNSEND (*Southampton; Gosport; London; Portsmouth, UK*)

MicroRNA-222 Regulates Cell Invasion by Targeting Matrix Metalloproteinase 1 (MMP1) and Manganese Superoxide Dismutase 2 (SOD2) in Tongue Squamous Cell Carcinoma Cell Lines. X. LIU, J. YU, L. JIANG, A. WANG, F. SHI, H. YE, X. ZHOU (*Chicago, IL, USA; Guangzhou, China*)

Increased levels of macrophage-secreted Cathepsin S during prostate cancer progression in TRAMP mice and patients. C. LINDAHL, M. SIMONSSON, A. BERGH, E. THYSELL, H. ANTTI, M. SUND, P. WIKSTRÖM (*Umeå, Sweden*)

Effect of Expressional Alteration of KAI1 on Breast Cancer Cell Growth, Adhesion, Migration and Invasion. F.A. MALIK, A.J SANDERS, M.A. KAYANI, W.G. JIANG (*Cardiff, Wales, UK; Islamabad, Pakistan*)

Gene Expression Profiling in Response to Estradiol and Genistein in Ovarian Cancer Cells. L. P. PARKER, D.D. TAYLOR, S. KERSTERSON, C. GERCEL-TAYLOR (*Louisville KY, USA*)

Differences in mRNA and microRNA Microarray Expression Profiles in Human Colon Adenocarcinoma HT-29 Cells Treated with either Intensity-modulated Radiation Therapy (IMRT), or Conventional Radiation Therapy (RT). F.E. AHMED, P.W. VOS, C. JEFFRIES, J.E. WILEY, D.A. WEIDNER, H. MOTA, C. BONNERUP (*Greenville; Chapel Hill, NC, USA*)

Chromosomal Alterations and Mutagen Sensitivity in Human Mucosal Cells of the Oropharynx and Lymphocytes caused by BPDE. M. REITER, P. BAUMEISTER, S. ZIEGER, U. HARREUS (*Munich, Germany*)

Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer. N. VALERI, C.M. CROCE, M. FABBRI (*Columbus, OH, USA; Ferrara; Meldola, Italy*)

PGF Isoforms, PLGF-1 and PGF-2, in Colorectal Cancer and the Prognostic Significance. A. ESCUDERO-ESPARZA, T.A. MARTIN, M.L. DAVIES, W.G. JIANG (*Cardiff, UK*)

MGMT Promoter Hypermethylation in a Series of 104 Glioblastomas. M. MELLAI, V. CALDERA, L. ANNOVAZZI, A. CHIÒ, M. LANOTTE, P. CASSONI, G. FINOCCHIARO, D. SCHIFFER (*Turin; Milan, Italy*)

Gene Expression Analysis of HCT116 Colon Tumor Derived Cells Treated with the Polyamine Analog PG-11047. N.A. IGNATENKO H.F. YERUSHALMI, R. PANDEY, K.L. KACHEL, D.E. STRINGER, L.J. MARTON, E.W. GERNER (*Tucson, AZ; Redwood City, CA, USA; Haifa, Israel*)

Diagnosis of Breast Cancer by Tear Proteomic Pattern. A. LEBRECHT, D. BOEHM, M. SCHMIDT, H. KOELBL, R.L. SCHWIRZ, F.H. GRUS (*Mainz, Germany*)

online from January 2009



**International Journal of Experimental and Clinical
Pathophysiology and Drug Research**

Published by the International Institute of Anticancer Research

ISSN: 0258-851X

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

Manuscripts and correspondence should be addressed to: Dr. J.G. Delinassios, Managing Editor, IN VIVO Editorial Office, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389. e-mail: journals@iilar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR website: www.iilar-anticancer.org

Selection of Recent Articles

Circulating Cytokine Levels In Prostate Cancer Patients Undergoing Radiation Therapy: Influence Of Neoadjuvant Total Androgen Suppression. R.M. JOHNKE J.M. EDWARDS, M.J. EVANS, G.N. NANGAMI, N.T.G. BAKKEN, J.M. KILBURN, T.-K. LEE, R.R. ALLISON, U.L. KARLSSON, H.H. ARASTU (*Greenville, NC, USA*)

Transgenic Mice Expressing Constitutively Active Akt in Oral Epithelium Validate Klf4 as a Potential Biomarker of Head and Neck Squamous Cell Carcinoma. M. MORAL, C. SEGRELLES, A.B. MARTÍNEZ-CRUZ, C. LORZ, *et al.* (*Madrid, Spain; Smithville, TX, USA*)

Detection of Herpesviruses and Parvovirus B19 in Gastric and Intestinal Mucosa of Chronic Fatigue Syndrome Patients. M. FRÉMONT, K. METZGER, H. RADY, J. HULSTAERT, K. DE MEIRLEIR (*Zellik; Brussels; Vilvoorde, Belgium*)

A Bioluminescent Orthotopic Mouse Model of Human Osteosarcoma that Allows Sensitive and Rapid Evaluation of New Therapeutic Agents In Vivo. K.E. COMSTOCK, C.L. HALL, S. DAIGNAULT, S.A. MANDLEBAUM, C. YU, E.T. KELLER (*Ann Arbor, MI, USA*)

Obesity Impairs Wound Healing in Ovariectomized Female Mice. V.B. HOLCOMB, V.A. KECK, J.C. BARRETT, J. HONG, S.K. LIBUTTI, N.P. NÚÑEZ (*Austin, TX; Bethesda, MD; Cambridge, MA; Bronx, NY, USA*)

Effectiveness of Combined Modality Radiotherapy of Orthotopic Human Squamous Cell Carcinomas in Nu/Nu Mice Using Cetuximab, Tirapazamine, and MnSOD-Plasmid Liposome Gene Therapy. M.W. EPPERLY, S.M. LAI, N. MASON, B. LOPRESI, T. DIXON, D. FRANICOLA, Y. NIU, W.R. WILSON, A.J. KANAI, J.S. GREENBERGER (*Pittsburgh, PA, USA; Auckland, New Zealand*)

Inhibiting Platelet Derived Growth Factor Beta (PDGFR-B) Decreases Ewing's Sarcoma Growth and Metastasis in a Novel Orthotopic Human Xenograft Model. Y.X. WANG, D. MANDAL, S. WANG, D. HUGHES, R.E. POLLOCK, D. LEV, E. KLEINERMAN, A. HAYES-JORDAN (*Houston, TX; Kingston, RI, USA*)

Ethyl-eicosapentaenoic Acid Reduces Liver Lipids and Lowers Plasma Levels of Lipids in Mice fed a High-fat Diet. N. NEMOTO, S. SUZUKI, H. KIKUCHI, H. OKABE, S. SASSA, S. SAKAMOTO (*Chiba; Tokyo, Japan*)

Management of Pseudomyxoma Peritonei by Cytoreduction+HIPEC (Hyperthermic Intraperitoneal Chemotherapy): Results Analysis of a Twelve-Year Experience. M. VAIRA, T. CIOPPA, G. DE MARCO, C. BING, S. D'AMICO, M. D'ALESSANDRO, G. FIORENTINI, M. DE SIMONE (*Florence; Italy*)

Dietary Calcium Source Influences Body Composition, Glucose Metabolism and Hormone Levels in a Mouse Model of Postmenopausal Obesity. R.E. DE ANGEL, D. BERRIGAN, N.P. NÚÑEZ, S.D. HURSTING, S.N. PERKINS (*Austin; Smithville, TX; Bethesda, MD, USA*)

Distribution of [³H]-Corticosterone in Urine, Feces and Blood of Male Sprague-Dawley Rats After Tail Vein and Jugular Vein Injections. K.S.P. ABELSON, S.S. FARD, J. NYMAN, R. GOLDKUHL, J. HAU (*Uppsala, Sweden; Copenhagen, Denmark*)

5-Hydroxymethylfurfural and 5-Sulfooxymethylfurfural Increase Adenoma and Flat ACF Number in the Intestine of Min/+ Mice. C. RØNNINGBORG, T. HUS-Y, H. GLATT, J.E. PAULSEN, J. ALEXANDER (*Oslo, Norway; Nuthetal, Germany*)

Ocular Toxicity Caused by Paclitaxel in Neonatal Sprague-Dawley Rats. M. KUWATA, K. YOSHIZAWA, M. MATSUMURA, K. TAKAHASHI, A. TSUBURA (*Osaka, Japan*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. Anticancer Res 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: Receptors for Reproductive Hormones (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios

International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2009 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Salvage Chemotherapy with Oxaliplatin and Capecitabine for Breast Cancer Patients Pretreated with Anthracyclines and Taxanes. A. POLYZOS, H. GOGAS, C. MARKOPOULOS, N. TSAVARIS, O. PAPADOPoulos, K. POLYZOS, A. GIANNOPoulos (<i>Athens, Greece</i>)	2851
Impact of Catechol- <i>O</i> -methyltransferase (<i>COMT</i>) Gene Polymorphism on Promoter Methylation Status in Gastric Mucosa. T. TAHARA, T. SHIBATA, T. ARISAWA, M. NAKAMURA, H. YAMASHITA, D. YOSHIOKA, M. OKUBO, N. MARUYAMA, T. KAMANO, Y. KAMIYA, H. FUJITA, M. NAGASAKA, M. IWATA, K. TAKAHAMA, M. WATANABE, I. HIRATA (<i>Toyoake, Aichi, Japan</i>)	2857
Phase II Study of Weekly Paclitaxel as a Second-line Treatment for S-1-refractory Advanced Gastric Cancer. G. MATSUDA, C. KUNISAKI, H. MAKINO, M. FUKAHORI, J. KIMURA, T. SATO, T. OSHIMA, Y. NAGANO, S. FUJI, R. TAKAGAWA, T. KOSAKA, H.A. ONO, H. AKIYAMA, Y. ICHIKAWA (<i>Yokohama, Japan</i>)	2863
Phase I Study of Capecitabine, Carboplatin and Intensity-modulated Radiation Therapy for Head and Neck Cancer. C.Y. THOMAS, P. READ, G. PETRONI, J. REIBEL, P.A. LEVINE (<i>Charlottesville, VA, USA</i>)	2869

* Reviews (pages 2461, 2589, 2665, 2793, 2799, 2803, 2837)

Gastrointestinal Stromal Tumor with Chondroid Differentiation. G. PULCINI, V. VILLANACCI, E. ROSSI, F. GHEZA, E. CERVI, A.B. FERRARI, G. CERVI, G. BASSOTTI (<i>Brescia; Perugia, Italy</i>)	2761
Dominance of <i>EGFR</i> and Insignificant <i>KRAS</i> Mutations in Prediction of Tyrosine-kinase Therapy for NSCLC Patients Stratified by Tumor Subtype and Smoking Status. M. PESEK, L. BENESOVA, B. BELSANOVA, P. MUKENSNABL, F. BRUHA, M. MINARIK (<i>Pilsen; Prague, Czech Republic</i>)	2767
Docetaxel and S-1 as a First-line Treatment in Patients with Advanced or Recurrent Gastric Cancer. Y. TSUTANI, M. OHARA, T. SUZUKI, K. MINAMI, E. MIYAHARA, A. KAMEDA, Y. NOSO (<i>Hiroshima, Japan</i>)	2775
Complete Pelvic Lymphadenectomy in Patients with Clinical Early, Grade I and II Endometrioid Corpus Cancer. S. FOTIOU, E.L. TRIMBLE, K. PAPAKONSTANTINOU, A. KONDI-PAFITI, T. PANOSKALTSIS, G. DELICONSTANTINOS, G. CREATSAS (<i>Athens, Greece; Bethesda, MD, USA</i>)	2781
Prospective Pilot-study of Combined Bipolar Radiofrequency Ablation and Application of Bone Cement in Bone Metastases. D. PROSCHEK, A. KURTH, P. PROSCHEK, T.J. VOGL, M.G. MACK (<i>Mainz; Frankfurt, Germany</i>)	2787
* Review: Brain Metastases from Epithelial Ovarian Cancer: Overview and Optimal Management. K. PIETZNER, G. OSKAY-OEZCELIK, K. EL KHALFAOUI, D. BOEHMER, W. LICHTENEGGER, J. SEHOULI (<i>Berlin, Germany</i>)	2793
* Review: Evidence-based Perioperative Management: Strategic Shifts in Times of Fast Track Surgery. S.S. CHOPRA, S.C. SCHMIDT, C. FOTOPOULOU, J. SEHOULI, G. SCHUMACHER (<i>Berlin, Germany</i>)	2799
* Review: Pros and Cons of Intraperitoneal Chemotherapy in the Treatment of Epithelial Ovarian Cancer. A.G. ZEIMET, D. REIMER, A.C. RADL, A. REINTHALLER, C. SCHAUER, E. PETRU, N. CONCIN, S. BRAUN, C. MARTH (<i>Innsbruck; Vienna; Graz, Austria</i>)	2803
Surgical Outcome and Survival Analysis of Young Patients with Primary Epithelial Ovarian Cancer. C. FOTOPOULOU, K. SAVVATIS, G. SCHUMACHER, W. LICHTENEGGER, J. SEHOULI (<i>Berlin, Germany</i>)	2809
Prognostic Significance of CA-125 in the Management of Patients with Recurrent Epithelial Ovarian Carcinoma Selected for Secondary Cytoreduction. S. MAHNER, L. WOELBER, S. JUNG, C.Z. EULENBURG, M. IHNNEN, J. SCHWARZ, J. SEHOULI, F. JAENICKE (<i>Hamburg; Berlin, Germany</i>)	2817
Surgical Management of Multiple Bilateral Fibroadenoma of the Breast: The Ribeiro Technique Modified by Rezai. O. CAMARA, A. EGBE, I. KOCH, J. HERRMANN, M. GAJDA, P. BALTZER, I.B. RUNNEBAUM (<i>Jena, Germany</i>)	2823
Venous Coupler for Free-flap Anastomosis. O. CAMARA, J. HERRMANN, A. EGBE, I. KOCH, M. GAJDA, I.B. RUNNEBAUM (<i>Jena, Germany</i>)	2827
Pros and Cons for Systemic Therapy in Recurrent Ovarian Cancer. G. OSKAY-ÖZCELIK, J. SEHOULI (<i>Berlin, Germany</i>)	2831
* Review: Controversies in the Management of Ovarian Cancer – Pros and Cons for Lymph Node Dissection in Ovarian Cancer. O. CAMARA, J. SEHOULI (<i>Berlin, Germany</i>)	2837
Circulating <i>hTERT</i> DNA in Early Breast Cancer. R. DIVELLA, S. TOMMASI, R. LACALAMITA, A. DANIELE, I. ABBATE, V.M. GARRISI, E. SAVINO, M. COVIELLO, V. RUBINI, G. SIMONE, A. PARADISO, M. QUARANTA (<i>Bari, Italy</i>)	2845

Impact of Interstitial Lung Disease on Survival for Patients with Non-small Cell Lung Cancer. K. MIYAZAKI, H. SATOH, K. KURISHIMA, R. NAKAMURA, H. ISHIKAWA, K. KAGOHASHI, G. OHARA, N. HIZAWA (<i>Ibaraki, Japan</i>)	2671
Side-effects of Pre-operative Epirubicin-Paclitaxel Therapy in Primary Breast Cancer Associated with Tumor Biology. M. WARM, R. KATES, A. THOMAS, T. FISCHER, N. HARBECK (<i>Cologne; Otterfing; Berlin, Germany</i>)	2675
Cisplatin–Ifosfamide–Gemcitabine as Salvage Chemotherapy in Ovarian Cancer Patients Pretreated with Platinum Compounds and Paclitaxel. A. POLYZOS, N. TSAVARIS, H. GOGAS, A. LAGADAS, K. POLYZOS, K. GIANNAKOPOULOS, E. FELEKOURAS, C. TSIGRIS, T. KARATZAS, O. PAPADOPoulos, A. GIANNOPoulos (<i>Athens, Greece</i>)	2681
Preoperative Leukocytosis, Anemia and Thrombocytosis Are Associated with Poor Survival in Non-small Cell Lung Cancer. M. TOMITA, T. SHIMIZU, M. HARA, T. AYABE, T. ONITSUKA (<i>Miyazaki, Japan</i>)	2687
Biological and Clinical Features in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-analysis. M.C. GARASSINO, K. BORGONOVO, A. ROSSI, A. MANCUSO, O. MARTELLI, A. TINAZZI, S. DI COSIMO, N. LA VERDE, P. SBURLATI, C. BIANCHI, G. FARINA, V. TORRI (<i>Avellino; Milan, Italy</i>)	2691
Clinical Characteristics of Laryngeal Cancer in <i>BRCA-1</i> Mutation Carriers. E. JAWOROWSKA, C. TARNOWSKA, J. LUBIŃSKI, P. SERRANO-FERNANDEZ, T. HUZARSKI, B. GÓRSKI, B. MASOJĆ, J. JAKUBISZYN, A. KORYTOWSKA, A. KRAM, J. RABCZYNSKI, J. LUBIŃSKI (<i>Szczecin; Opole; Poznań; Wrocław, Poland</i>)	2703
Altered Calcium Metabolism in Patients on Long-term Bisphosphonate Therapy for Metastatic Breast Cancer. C. SIMMONS, E. AMIR, G. DRANITSARIS, M. CLEMONS, B. WONG, R. VEITH, D.E.C. COLE (<i>Toronto, ON, Canada</i>)	2707
Decrease of E-Cadherin Expression in Canine Cutaneous Histiocytoma Appears to be Related to its Spontaneous Regression. I. PIRES, F.L. QUEIROGA, A. ALVES, F. SILVA, C. LOPES (<i>Vila Real; Porto, Portugal</i>)	2713
Fifty-five Minimally Invasive Esophagectomies: A Single Centre Experience. S.F. SCHOPPMANN, G. PRAGER, F. LANGER, M. RIEGLER, E. FLEISCHMAN, J. ZACHERL (<i>Vienna, Austria</i>)	2719
Review: Colorectal Cancer and Inflammatory Bowel Disease: Epidemiology, Risk Factors, Mechanisms of Carcinogenesis and Prevention Strategies. J.K. TRIANTAFILLIDIS, G. NASIOULAS, P.A. KOSMIDIS (<i>Athens, Greece</i>)	2727
Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer. K. OBA, M. KOBAYASHI, T. MATSUI, Y. KODERA, J. SAKAMOTO (<i>Kyoto; Kochi; Okazaki; Nagoya, Japan</i>)	2739
Gefitinib Plus Paclitaxel after Failure of Gefitinib in Non-small Cell Lung Cancer Initially Responding to Gefitinib. T. SHUKUYA, T. TAKAHASHI, A. TAMIYA, A. ONO, S. IGAWA, Y. NAKAMURA, A. TSUYA, H. MURAKAMI, T. NAITO, K. KAIRA, M. ENDO, N. YAMAMOTO (<i>Shizuoka, Japan</i>)	2747
DYRK2 Expression May be a Predictive Marker for Chemotherapy in Non-small Cell Lung Cancer. S.-I. YAMASHITA, M. CHUJO, T. MOROGA, K. ANAMI, K. TOKUISHI, M. MIYAWAKI, Y. KAWANO, S. TAKENO, S. YAMAMOTO, K. KAWAHARA (<i>Yufu, Oita, Japan</i>)	2753
Efficacy of a Lumbo-peritoneal Shunt for Meningeal Carcinomatosis Refractory to Gefitinib Treatment. T. KUBO, N. TAKIGAWA, K. KIURA, A. NISHIDA, N. OCHI, H. KASHIHARA, S. UMEMURA, A. HISAMOTO, M. TANIMOTO (<i>Okayama, Japan</i>)	2759

Chemotherapy Response Evaluation in Metastatic Colorectal Cancer with FDG PET/CT and CT Scans. J. MONTEIL, N. MAHMOUDI, S. LEOBON, P.Y. ROUDAUT, A. EL BADAOUI, S. VERBEKE, L. VENAT-BOUDET, J. MARTIN, V. LE BRUN-LY, S. LAVAU-DENES, A. MAUBON, P. BOUILLET, M. POUQUET, J.C. VANDROUX, N. TUBIANA-MATHIEU (<i>Limoges, France</i>)	2563
Anaemia and Other Predictors of Fatigue Among Patients on Palliative Therapy for Advanced Cancer. A. LATVALA, K. SYRJÄNEN, H. SALMENOJA, E. SALMINEN (<i>Turku, Finland</i>)	2569
Discrepancies in Expression and Prognostic Value of Tumor Markers in Adenocarcinoma and Squamous Cell Carcinoma in Cervical Cancer. A.K. LINDSTRÖM, T. TOT, U. STENDAHL, S. SYRJÄNEN, K. SYRJÄNEN, D. HELLBERG (<i>Falun; Umeå; Uppsala, Sweden; Turku, Finland</i>)	2577
Insulin-like Growth Factor-binding Protein-3 in Osteosarcomas and Normal Bone Tissues. S. RESSLER, J. RADHI, T. AIGNER, C. LOO, W. ZWERSCHKE, C. SERGI (<i>Innsbruck, Austria; Hamilton, ON; Edmonton, AB, Canada; Leipzig, Germany; Herston, QLD, Australia</i>)	2579
* Review: New Markers and Multivariate Models for Prostate Cancer Detection. C. STEPHAN, H. RITTENHOUSE, H. CAMMANN, M. LEIN, M. SCHRADER, S. DEGER, K. MILLER, K. JUNG (<i>Berlin, Germany; Diego, CA, USA</i>)	2589
Amitriptyline in the Prevention of Chemotherapy-induced Neuropathic Symptoms. A.-L. KAUTIO, M. HAANPÄÄ, A. LEMINEN, E. KALSO, H. KAUTIAINEN, T. SAARTO (<i>Helsinki; Tampere; Jyväskylä, Finland</i>)	2601
Pseudoprogression and <i>MGMT</i> Status in Glioblastoma Patients: Implications in Clinical Practice. A. FABI, M. RUSSILLO, G. METRO, A. VIDIRI, S. DI GIOVANNI, F. COGNETTI (<i>Rome, Italy</i>)	2607
Efficacy of Orally Administered Superfine Dispersed Lentinan (β -1,3-Glucan) for the Treatment of Advanced Colorectal Cancer. S. HAZAMA, S. WATANABE, M. OHASHI, M. YAGI, M. SUZUKI, K. MATSUDA, T. YAMAMOTO, Y. SUGA, T. SUGA, S. NAKAZAWA, M. OKA (<i>Yamaguchi; Sapporo; Hokkaido; Niigata; Ishikawa; Wakayama; Kanagawa; Tokyo; Aichi, Japan</i>)	2611
Quantitative Analysis of Tumor-derived Methylated <i>RUNX3</i> Sequences in the Serum of Gastric Cancer Patients. C. SAKAKURA, T. HAMADA, K. MIYAGAWA, M. NISHIO, A. MIYASHITA, H. NAGATA, H. IDA, S. YAZUMI, E. OTSUJI, T. CHIBA, K. ITO, Y. ITO (<i>Kyoto; Nagasaki, Japan; Singapore, Singapore</i>)	2619
Definitive Conformal Radiotherapy for Localized Prostate Cancer: A Long-term Follow-up Study. C.M.C. DEICHMUELLER, G. WEGENER, J.H. KARSTENS, F. BRUNS (<i>Hannover, Germany</i>)	2627
VEGF in Patients with Non-small Cell Lung Cancer during Combination Chemotherapy of Carboplatin and Paclitaxel. M. SHINGYOJI, S. ANDO, H. NISHIMURA, T. NAKAJIMA, A. ISHIKAWA, M. ITAKURA, T. IIZASA, H. KIMURA (<i>Chiba, Japan</i>)	2635
Does Distance to Treatment Centre Influence the Rate of Palliative Radiotherapy in Adult Cancer Patients? C. NIEDER, J. NORUM, O. SPANNE, I. BILBERG, G. VAGSTAD, A. DALHAUG (<i>Bodø; Tromsø, Norway</i>)	2641
Prospective Study on Neck Dissection after Primary Chemoradiation Therapy in Stage IV Pharyngeal Cancer. M. BREMKE, P.J. BARTH, A.M. SESTERHENN, V. BUDACH, R. ENGENHART-CABILLIC, J.A. WERNER (<i>Marburg; Berlin, Germany</i>)	2645
Giant Basal Cell Carcinoma: Clinicopathological Analysis of 51 Cases and Review of the Literature. M. ARCHONTAKI, S.D. STAVRIANOS, D.P. KORKOLIS, N. ARNOGIANNAKI, V. VASSILIADIS, I.E. LIAPAKIS, H. CHRIST, A.D. RAPIDIS, G. KOKKALIS (<i>Athens, Greece; Köln, Germany</i>)	2655
* Review: Novel Strategy of Anti-angiogenic Therapy for Uterine Cervical Carcinomas. J. FUJIMOTO (<i>Gifu, Japan</i>)	2665

Expression of JNK-interacting Protein JIP-1 and Insulin-like Growth Factor II in Wilms Tumour Cell Lines and Primary Wilms Tumours. W. ENGSTRÖM, M. GRANERUS (<i>Uppsala, Sweden</i>)	2467
Toll-like Receptor 4 Activation Increases Akt Phosphorylation in Colon Cancer Cells. H.Q. DOAN, K.A. BOWEN, L.A. JACKSON, B.M. EVERIS (<i>Galveston, TX, USA</i>)	2473
<i>MYC</i> Insertions in Diffuse-type Gastric Adenocarcinoma. D.Q. CALCAGNO, A.C. GUIMARÃES, M.F. LEAL, A.D. SEABRA, A.S. KHAYAT, T.B. PONTES, P.P. ASSUMÇÃO, M. DE ARRUDA CARDOSO SMITH, R.R. BURBANO (<i>Belém, PA; São Paulo, SP, Brazil</i>)	2479
Panaxanthone Isolated from Pericarp of <i>Garcinia mangostana</i> L. Suppresses Tumor Growth and Metastasis of a Mouse Model of Mammary Cancer. H. DOI, M.-A. SHIBATA, E. SHIBATA, J. MORIMOTO, Y. AKAO, M. IINUMA, N. TANIGAWA, Y. OTSUKI (<i>Osaka; Gifu, Japan</i>)	2485
Conversion of Prostate Cancer from Hormone Independence to Dependency Due to AMACR Inhibition: Involvement of Increased AR Expression and Decreased IGF1 Expression. K. TAKAHARA, H. AZUMA, T. SAKAMOTO, S. KIYAMA, T. INAMOTO, N. IBUKI, T. NISHIDA, H. NOMI, TA. UBAI, N. SEGAWA, Y. KATSUOKA (<i>Osaka, Japan</i>)	2497
Doxorubicin and Congo Red Effectiveness on Prion Infectivity in Golden Syrian Hamster. M. CORATO, P. OGLIARI, F. CECILIANI, E. COVA, V. BELLOTTI, C. CEREDA, G. MERLINI, M. CERONI (<i>Pavia; Milan, Italy</i>)	2507
Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in Lung Tissue of Patients with Non-small Cell Lung Cancer (NSCLC) and Benign Pulmonary Disease. J. SAFRANEK, M. PESTA, L. HOLUBEC, V. KULDA, J. DRESLEROVA, J. VRZALOVA, O. TOPOLCAN, M. PESEK, J. FINEK, V. TRESKA (<i>Pilsen, Czech Republic</i>)	2513
Role of <i>L-MYC</i> Polymorphism in Oral Squamous Cell Carcinoma in Turkey. K. BEKTAŞ-KAYHAN, M. ÜNÜR, İ. YAYLIM-ERALTAN, A. ERGEN, G. HAFİZ, A. KARADENİZ, T. İSBİR (<i>İstanbul, Turkey</i>)	2519
Expression of Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase in Human Breast Carcinoma Cells and Tissues. W.T.Y. LOO, L.W.C. CHOW, T. SUZUKI, K. ONO, T. ISHIDA, H. HIRAKAWA, N. OHUCHI, H. SASANO (<i>Sendai, Japan; Hong Kong, PRC</i>)	2525
Abnormal Expression of Fibrinogen Gamma (FGG) and Plasma Level of Fibrinogen in Patients with Hepatocellular Carcinoma. W.-L. ZHU, B.-L. FAN, D.-L. LIU, W.-X. ZHU (<i>Xinxiang; Zhengzhou, P.R. of China</i>)	2531
O ⁶ -Methylguanine-DNA Methyltransferase Hypermethylation Modulated by 17β-Estradiol in Lung Cancer Cells. J.-C. LAI, J.-Y. WU, Y.-W. CHENG, K.-T. YEH, T.-C. WU, C.-Y. CHEN, H. LEE (<i>Taichung; Changhua, Taiwan, ROC</i>)	2535
Development of a Novel Cell-based Assay to Evaluate the Malignant Potential of Cancer <i>In Vitro</i> . C. HIRAKAWA, K. TANAKA, Y. TAKAYA, S. NAKAGAWA, Y. KATAOKA, Y. TAGAWA, M. NIWA (<i>Nagasaki; Fukuoka, Japan</i>)	2541
Clinical Studies	
Significance of S100A4 as a Prognostic Marker of Lung Squamous Cell Carcinoma. M. TSUNA, S.-I. KAGEYAMA, J. FUKUOKA, H. KITANO, Y. DOKI, H. TEZUKA, H. YASUDA (<i>Kanagawa; Toyama; Yamanashi, Japan</i>)	2547
Preoperative Chemoradiotherapy for Esophageal Cancer: Factors Associated with Clinical Response and Postoperative Complications. M. MORITA, T. MASUDA, S. OKADA, K. YOSHINAGA, H. SAEKI, E. TOKUNAGA, K. ENDO, Y. EMI, Y. KAKEJI, Y. MAEHARA (<i>Fukuoka, Japan</i>)	2555